ACTRN12616000204448Terminated未知
A pragmatic, multi-centre, parallel design (1:1:1), open, randomised controlled trial to evaluate the effectiveness of a simple short message service (sms) vs tailored sms and home visiting compared to usual parent/carer practice to improve the uptake and timeliness of the primary immunisation series in children aged less than 2 years
Queensland University of Technology0 sites516 target enrollmentStarted: February 16, 2016Last updated:
Conditions
Trial Snapshot
- Phase
- 未知
- Status
- Terminated
- Enrollment
- 516
Study Overview
Brief Summary
No summary available.
Study Design
- Study Type
- Interventional
- Allocation
- Randomised controlled trial
- Primary Purpose
- Prevention
- Masking
- Open (masking not used)
Eligibility Criteria
- Ages
- 12 Years to 45 Years (—)
- Sex
- Female
Inclusion Criteria
- •(i) Mother in the 2nd or 3rd trimester of pregnancy
- •(ii) Not planning to move from the study area until the infant turns 8 months of age
- •(iii) Access to a mobile phone
- •(iv) Provision of written informed consent from the mother
- •(v) Caboolture Community Medical l or Carbal are the family’s usual health care provider.
- •(vii) For the RCT component, a live born infant
Exclusion Criteria
- •None will apply
Investigators
Similar Trials
Recruiting
Unknown
A multicenter, randomized, parallel design, double-blind, superiority test, prospective clinical trial to confirm the safety and effectiveness of symptom improvement when applying low-output light irradiation device (Bye-Vi) to cold patients.KCT0008894anobioimaging58
Completed
Not Applicable
Eficacia de TAK-559 en el tratamiento de sujetos con diabetes mellitus tipo 2.-E149 Unspecified diabetes mellitus, without complicationsUnspecified diabetes mellitus, without complicationsE149PER-087-03TAKEDA PHARMACEUTICALS,
Completed
Not Applicable
A STUDY OF PARALLEL DESIGN, MULTICENTER, DOUBLE BLIND, RANDOMIZED, CONTROLLED ON THE SAFETY AND EFFICACY OF TAK-559 COMPARED WITH PLACEBO IN THE TREATMENT OF PATIENTS WITH DIABETES MELLITUS TYPE 2.-E149 Unspecified diabetes mellitus, without complicationsUnspecified diabetes mellitus, without complicationsE149PER-089-03TAKEDA GLOBAL RESEARCH & DEVELOPMENT CENTER, INC.,
Recruiting
Not Applicable
Donepezil for Visuospatial dysfunction in Mild Cognitive ImpairmentDiseases of the nervous systemKCT0006236Jeonbuk National University Hospital70
Active, not recruiting
Phase 1
A multi-centre, randomized, two-armed, parallel group and evaluator-blinded study of efficacy and safety of topical MOB015B in the treatment of mild to moderate distal subungual onychomycosis (DSO )Distal Subungual OnychomycosisMedDRA version: 20.0Level: PTClassification code 10030338Term: OnychomycosisSystem Organ Class: 10021881 - Infections and infestationsEUCTR2016-001204-39-DEMoberg Pharma AB (publ)452